| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-09-09 02:58:41 UTC |
|---|
| Update Date | 2022-11-30 19:25:57 UTC |
|---|
| HMDB ID | HMDB0114882 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | PA(18:0/20:1(11Z)) |
|---|
| Description | PA(18:0/20:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:0/20:1(11Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of eicosenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. |
|---|
| Structure | [H][C@@](COC(=O)CCCCCCCCCCCCCCCCC)(COP(O)(O)=O)OC(=O)CCCCCCCCC\C=C/CCCCCCCC InChI=1S/C41H79O8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(43)49-39(38-48-50(44,45)46)37-47-40(42)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h17,19,39H,3-16,18,20-38H2,1-2H3,(H2,44,45,46)/b19-17-/t39-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-Stearoyl-2-eicosenoyl-sn-glycero-3-phosphate | HMDB | | 1-Stearoyl-2-eicosenoyl-sn-phosphatidic acid | HMDB | | PA(18:0/20:1) | HMDB | | PA(18:0/20:1N9) | HMDB | | PA(18:0/20:1W9) | HMDB | | PA(38:1) | HMDB | | Phosphatidic acid(18:0/20:1(11Z)) | HMDB | | Phosphatidic acid(18:0/20:1) | HMDB | | Phosphatidic acid(18:0/20:1n9) | HMDB | | Phosphatidic acid(18:0/20:1W9) | HMDB | | Phosphatidic acid(38:1) | HMDB | | Phosphatidate(18:0/20:1(11Z)) | HMDB | | Phosphatidate(18:0/20:1) | HMDB | | Phosphatidate(18:0/20:1N9) | HMDB | | Phosphatidate(18:0/20:1W9) | HMDB | | Phosphatidate(38:1) | HMDB | | 1-stearoyl-2-eicosenoyl-sn-glycero-3-phosphate | SMPDB, HMDB | | 1-stearoyl-2-eicosenoyl-sn-phosphatidic acid | SMPDB, HMDB | | PA(18:0/20:1) | SMPDB, HMDB | | PA(18:0/20:1n9) | SMPDB, HMDB | | PA(18:0/20:1w9) | SMPDB, HMDB | | PA(38:1) | SMPDB, HMDB | | Phosphatidic acid(18:0/20:1(11Z)) | SMPDB, HMDB | | Phosphatidic acid(18:0/20:1) | SMPDB, HMDB | | Phosphatidic acid(18:0/20:1n9) | SMPDB, HMDB | | Phosphatidic acid(18:0/20:1w9) | SMPDB, HMDB | | Phosphatidic acid(38:1) | SMPDB, HMDB | | Phosphatidate(18:0/20:1(11Z)) | SMPDB, HMDB | | Phosphatidate(18:0/20:1) | SMPDB, HMDB | | Phosphatidate(18:0/20:1n9) | SMPDB, HMDB | | Phosphatidate(18:0/20:1w9) | SMPDB, HMDB | | PA(18:0/20:1(11Z)) | SMPDB |
|
|---|
| Chemical Formula | C41H79O8P |
|---|
| Average Molecular Weight | 731.049 |
|---|
| Monoisotopic Molecular Weight | 730.551256502 |
|---|
| IUPAC Name | [(2R)-2-[(11Z)-icos-11-enoyloxy]-3-(octadecanoyloxy)propoxy]phosphonic acid |
|---|
| Traditional Name | (2R)-2-[(11Z)-icos-11-enoyloxy]-3-(octadecanoyloxy)propoxyphosphonic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@@](COC(=O)CCCCCCCCCCCCCCCCC)(COP(O)(O)=O)OC(=O)CCCCCCCCC\C=C/CCCCCCCC |
|---|
| InChI Identifier | InChI=1S/C41H79O8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(43)49-39(38-48-50(44,45)46)37-47-40(42)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h17,19,39H,3-16,18,20-38H2,1-2H3,(H2,44,45,46)/b19-17-/t39-/m1/s1 |
|---|
| InChI Key | OVIWGVWBGSAIEW-VEAYGOGPSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1,2-diacylglycerol-3-phosphates. These are glycerol-3-phosphates in which the glycerol moiety is bonded to two aliphatic chains through ester linkages. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Glycerophospholipids |
|---|
| Sub Class | Glycerophosphates |
|---|
| Direct Parent | 1,2-diacylglycerol-3-phosphates |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,2-diacylglycerol-3-phosphate
- Fatty acid ester
- Monoalkyl phosphate
- Dicarboxylic acid or derivatives
- Fatty acyl
- Alkyl phosphate
- Phosphoric acid ester
- Organic phosphoric acid derivative
- Carboxylic acid ester
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Organooxygen compound
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Naturally occurring processBiological processBiochemical pathwayMetabolic pathway- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0065966)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/22:0) (PathBank: SMP0065968)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z)) (PathBank: SMP0065971)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0065973)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/24:1(15Z)) (PathBank: SMP0065976)
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:1(11Z)) (PathBank: SMP0071739)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:3(8Z,11Z,14Z)) (PathBank: SMP0074715)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0074725)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/24:0) (PathBank: SMP0074726)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0089985)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(11Z)/22:0) (PathBank: SMP0099297)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(11Z)/22:1(13Z)) (PathBank: SMP0099298)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:3(5Z,8Z,11Z)) (PathBank: SMP0065963)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0065967)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/22:1(13Z)) (PathBank: SMP0065969)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0074723)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:1(11Z)) (PathBank: SMP0089981)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/22:2(13Z,16Z)) (PathBank: SMP0089990)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/22:1(13Z)/22:1(13Z)) (PathBank: SMP0099308)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:2(11Z,14Z)) (PathBank: SMP0065962)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(11Z)/20:1(11Z)) (PathBank: SMP0099294)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/22:0/22:1(13Z)) (PathBank: SMP0099307)
- Phosphatidylcholine Biosynthesis PC(18:0/20:1(11Z)) (PathBank: SMP0063837)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/22:0/22:0) (PathBank: SMP0099306)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/18:0) (PathBank: SMP0018486)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:0) (PathBank: SMP0018487)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/14:1(9Z)) (PathBank: SMP0018490)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/16:1(9Z)) (PathBank: SMP0018491)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/18:1(11Z)) (PathBank: SMP0018492)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/18:1(9Z)) (PathBank: SMP0018493)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/18:2(9Z,12Z)) (PathBank: SMP0018497)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/18:3(6Z,9Z,12Z)) (PathBank: SMP0018498)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/18:3(9Z,12Z,15Z)) (PathBank: SMP0018502)
- De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z)) (PathBank: SMP0018503)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(11Z)/20:1(13Z)) (PathBank: SMP0081498)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(13Z)/20:1(13Z)) (PathBank: SMP0081501)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(13Z)/22:0) (PathBank: SMP0081502)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(13Z)/22:1(13Z)) (PathBank: SMP0081503)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0099295)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099296)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0099299)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099300)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:0) (PathBank: SMP0099301)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z)) (PathBank: SMP0099302)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099303)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:0) (PathBank: SMP0099304)
- Cardiolipin Biosynthesis CL(18:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z)) (PathBank: SMP0099305)
|
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 9.54 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 36.9603 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.08 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 5317.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 638.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 388.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 263.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1083.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1835.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1532.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 248.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 3730.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 1135.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2977.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1419.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 751.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 764.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 860.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.7 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| PA(18:0/20:1(11Z)),1TMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)O[Si](C)(C)C | 5154.8 | Semi standard non polar | 33892256 | | PA(18:0/20:1(11Z)),1TMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)O[Si](C)(C)C | 4566.4 | Standard non polar | 33892256 | | PA(18:0/20:1(11Z)),1TMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)O[Si](C)(C)C | 6013.1 | Standard polar | 33892256 | | PA(18:0/20:1(11Z)),2TMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 5110.8 | Semi standard non polar | 33892256 | | PA(18:0/20:1(11Z)),2TMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 4550.0 | Standard non polar | 33892256 | | PA(18:0/20:1(11Z)),2TMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 5251.8 | Standard polar | 33892256 | | PA(18:0/20:1(11Z)),1TBDMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)O[Si](C)(C)C(C)(C)C | 5399.7 | Semi standard non polar | 33892256 | | PA(18:0/20:1(11Z)),1TBDMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)O[Si](C)(C)C(C)(C)C | 4662.8 | Standard non polar | 33892256 | | PA(18:0/20:1(11Z)),1TBDMS,isomer #1 | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)O[Si](C)(C)C(C)(C)C | 5986.3 | Standard polar | 33892256 |
|
|---|
| General References | - Moritz A, De Graan PN, Gispen WH, Wirtz KW: Phosphatidic acid is a specific activator of phosphatidylinositol-4-phosphate kinase. J Biol Chem. 1992 Apr 15;267(11):7207-10. [PubMed:1313792 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Divecha N, Irvine RF: Phospholipid signaling. Cell. 1995 Jan 27;80(2):269-78. [PubMed:7834746 ]
- Moolenaar WH, Kruijer W, Tilly BC, Verlaan I, Bierman AJ, de Laat SW: Growth factor-like action of phosphatidic acid. Nature. 1986 Sep 11-17;323(6084):171-3. [PubMed:3748188 ]
- Yang CY, Frohman MA: Mitochondria: signaling with phosphatidic acid. Int J Biochem Cell Biol. 2012 Aug;44(8):1346-50. doi: 10.1016/j.biocel.2012.05.006. Epub 2012 May 15. [PubMed:22609101 ]
- Cevc, Gregor (1993). Phospholipids Handbook. Marcel Dekker.
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
|---|